Jun. 28, 2021. Shanghai, China. Shanghai Zhimeng Biopharma, Inc. announces the appointment of Ming Ren, MD, PhD, as Chief Medical Officer, overseeing disease/therapeutic strategies, clinical research and development of Zhimeng’s growing clinical pipeline in CNS and liver diseases.

Dr. Ren is a trained neurologist and has over 30 years of experience in basic and clinical research in the field of CNS diseases. He holds a medical license in neurology in both China and USA. As a leading researcher or an attending physician, Dr. Ren worked at the NIH, Uniformed Service University of Health Sciences, and Case Western Medical Center, USA, and in Chinese Military Medical University, Beijing Xuanwu Hospital Clinical Research Center. Prior to joining Zhimeng Biopharma, Dr. Ren was the Chief Medical Officer at Clinical Service Center (Beijing, China), responsible for the Center’s medical and clinical development in neurology, cardiology, and oncology.

“We are delighted to welcome Dr. Ming Ren to our management team at Zhimeng ”, commented Huanming Chen, founder and CEO of Shanghai Zhimeng Biopharma. “Dr. Ren is a medical expert in the areas of neurology and CNS diseases. His joining will greatly strengthen our ability to advance our drug candidates into clinical development. We wish Dr. Ren a great success at Zhimeng”.

“Zhimeng has got an experienced management team and has developed robust pipelines in CNS and liver disease areas. I am pleased to see the many progresses Zhimeng has made in a relatively short period of time since its inception in 2018. I am excited to join Zhimeng. With my many years of clinical and research experience in neurology, I will help speed up the clinical developments of Zhimeng’s dug candidates. We will try to bring the best medicines to patients”.